Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer

Furuse, Junji; Okusaka, Takuji; Bridgewater, John; Taketsuna, Masanori; Wasan, Harpreet; Koshiji, Minori; Valle, Juan W

doi:10.1016/j.critrevonc.2010.10.009

Cited by 33 publications

(22 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2010, a new standard of care in unresectable BTC was established with the reporting of the UK NCRI ABC-01 and ABC-02 trials 39 113 114. ABC-02 is the largest randomised phase III study reported in BTC to date.…”

Section: Treatmentmentioning

confidence: 99%

Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update

Khan

Davidson

Goldin

et al. 2012

Gut

Self Cite

698

666

View full text Add to dashboard Cite

show abstract

Section: Treatmentmentioning

confidence: 99%

Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update

Khan

Davidson

Goldin

et al. 2012

Gut

Self Cite

698

666

View full text Add to dashboard Cite

show abstract

“…9 Moreover, the use of adjuvant chemotherapy for CCA renders poor outcomes, and studies examining the effectiveness of treatment are conflicting. 10,11 At present, there is no standard protocol for successful treatment for CCA. Therefore, the development of new treatment strategies is required.…”

Section: Introductionmentioning

confidence: 99%

Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA

et al. 2017

View full text Add to dashboard Cite

Cholangiocarcinoma is a malignancy of bile duct epithelia with an increasing in incidence rate worldwide. Surgery is the only curative treatment, while adjuvant chemotherapy and radiotherapy render poor responses. Cell-based immunotherapy is a potential strategy for cholangiocarcinoma treatment. However, variation of tumor antigens in cholangiocarcinoma leads to the ineffectiveness of cell-based immunotherapy. In this study, we examined the activation of effector T-cells by dendritic cells pulsed with protein lysate or total RNA from cholangiocarcinoma cell lines for their cytolytic activity against cholangiocarcinoma. Broad-spectrum antigen types with respect to RNA antigen sources were obtained from combination of three cholangiocarcinoma cell lines (KKU-213, KKU-100, and KKU-055). Compared with protein lysate-pulsed dendritic cells, total RNA-pulsed dendritic cells induced anti-tumor effector T-cell response with higher killing ability to KKU-100 and KKU-213 cells compared with protein lysate-pulsed dendritic cells. Moreover, pooled messenger RNA from three cholangiocarcinoma cell lines significantly increased the specific killing capacity of activated lymphocytes against KKU-213 cells. These results suggest that activation of anti-tumor effector T-cells against cholangiocarcinoma by RNA-pulsed dendritic cells is more effective than that by protein lysate-pulsed dendritic cells. In addition, pulsing dendritic cells with pooled messenger RNA from multiple cell lines enhanced the efficacy of a cellular immune response against cholangiocarcinoma.

show abstract

“…Of note, performance status appears to affect outcome, with those patients of WHO performance status 2 not deriving any survival benefit. A Japanese study of 83 patients concluded similar results to ABC-02, albeit to nonsignificant levels [50]. An analysis study from the USA reported that direct medical costs, quality adjusted life years and patient time costs were similar for both CisGem and gemcitabine alone therapy [51].…”

Section: Palliative Chemotherapymentioning

confidence: 88%